Transcriptomic Landscape of Cisplatin-Resistant Neuroblastoma Cells

Authors

RODRIGO Miguel Angel Merlos BUCHTELOVA Hana JIMENEZ Ana Maria Jimenez ADAM Pavlina BABULA Petr HEGER Zbynek ADAM Vojtech

Year of publication 2019
Type Article in Periodical
Magazine / Source Cells
MU Faculty or unit

Faculty of Medicine

Citation
Web http://dx.doi.org/10.3390/cells8030235
Doi http://dx.doi.org/10.3390/cells8030235
Keywords neuroblastoma; cisplatin; chemoresistance; microarray; lysosomes; transport
Description The efficiency of cisplatin (CDDP) is significantly hindered by the development of resistance during the treatment course. To gain a detailed understanding of the molecular mechanisms underlying the development of cisplatin resistance, we comparatively analyzed established a CDDP-resistant neuroblastoma cell line (UKF-NB-4(CDDP)) and its susceptible parental cells (UKF-NB-4). We verified increased chemoresistance of UKF-NB-4(CDDP) cells by analyzing the viability, induction of apoptosis and clonal efficiency. To shed more light on this phenomenon, we employed custom cDNA microarray (containing 2234 probes) to perform parallel transcriptomic profiling of RNA and identified that 139 genes were significantly up-regulated due to CDDP chemoresistance. The analyses of molecular pathways indicated that the top up-regulation scoring functions were response to stress, abiotic stimulus, regulation of metabolic process, apoptotic processes, regulation of cell proliferation, DNA repair or regulation of catalytic activity, which was also evidenced by analysis of molecular functions revealing up-regulation of genes encoding several proteins with a wide-spectrum of enzymatic activities. Functional analysis using lysosomotropic agents chloroquine and bafilomycin A1 validated their potential to re-sensitize UKF-NB-4(CDDP) cells to CDDP. Taken together, the identification of alterations in specific genes and pathways that contribute to CDDP chemoresistance may potentially lead to a renewed interest in the development of novel rational therapeutics and prognostic biomarkers for the management of CDDP-resistant neuroblastoma.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info